279 related articles for article (PubMed ID: 33537861)
21. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
Karakulak UN; Aladağ E; Maharjan N; Övünç K
Turk Kardiyol Dern Ars; 2016 Jan; 44(1):71-4. PubMed ID: 26875134
[TBL] [Abstract][Full Text] [Related]
22. The Role of Vasospasm and Microcirculatory Dysfunction in Fluoropyrimidine-Induced Ischemic Heart Disease.
Fabin N; Bergami M; Cenko E; Bugiardini R; Manfrini O
J Clin Med; 2022 Feb; 11(5):. PubMed ID: 35268333
[TBL] [Abstract][Full Text] [Related]
23. Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.
Vaudo CE; Gil B; Galuski K; Zarwan C; Nugent FW
Pharmacotherapy; 2016 Nov; 36(11):e178-e182. PubMed ID: 27716991
[TBL] [Abstract][Full Text] [Related]
24. 5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations.
Teperikidis E; Boulmpou A; Charalampidis P; Tsavousoglou C; Giannakoulas G; Papadopoulos CE; Vassilikos V
Acta Cardiol; 2022 Feb; 77(1):1-13. PubMed ID: 33683181
[TBL] [Abstract][Full Text] [Related]
25. Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.
Franck C; Malfertheiner P; Venerito M
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28536214
[TBL] [Abstract][Full Text] [Related]
26. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
Saif MW; Garcon MC; Rodriguez G; Rodriguez T
In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
[TBL] [Abstract][Full Text] [Related]
27. [Fluoropyrimidines cardiac toxicity: 5-fluorouracil, capecitabine, compound S-1 and trifluridine/tipiracil].
Vaflard P; Ederhy S; Torregrosa C; André T; Cohen R; Lopez-Trabada D
Bull Cancer; 2018; 105(7-8):707-719. PubMed ID: 29960638
[TBL] [Abstract][Full Text] [Related]
28. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Deboever G; Hiltrop N; Cool M; Lambrecht G
Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
[TBL] [Abstract][Full Text] [Related]
29. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
Lampropoulou DI; Laschos K; Amylidi AL; Angelaki A; Soupos N; Boumpoucheropoulos S; Papadopoulou E; Nanou E; Zidianakis V; Nasioulas G; Fildissis G; Aravantinos G
J Oncol Pharm Pract; 2020 Apr; 26(3):747-753. PubMed ID: 31382864
[TBL] [Abstract][Full Text] [Related]
30. Case report: Uridine triacetate in the management of delayed onset 5-fluorouracil toxicity: A case report and review of literature.
Jacob A; Sekkath Veedu J; Selene I; Raj R; Kannan L; Patel R
Front Pharmacol; 2022; 13():977734. PubMed ID: 36160401
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for fluoropyrimidine-induced cardiotoxicity in colorectal cancer: A retrospective cohort study and establishment of a prediction nomogram for 5-FU induced cardiotoxicity.
Wang Y; Wang W; Dong H; Wang G; Chen W; Chen J; Chen W
Front Oncol; 2023; 13():1017237. PubMed ID: 36937428
[TBL] [Abstract][Full Text] [Related]
32. 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation.
Sasson Z; Morgan CD; Wang B; Thomas G; MacKenzie B; Platts ME
Can J Cardiol; 1994 Oct; 10(8):861-4. PubMed ID: 7954023
[TBL] [Abstract][Full Text] [Related]
33. An unusual case of acute myopericarditis after the first dose of capecitabine: Need for new cardioprotective strategies and risk stratification.
Meter M; Gavran I; Bajo D; Duplancic D
Int J Clin Pharmacol Ther; 2021 Dec; 59(12):775-779. PubMed ID: 34503643
[TBL] [Abstract][Full Text] [Related]
34. EVALUATION OF 5-FLUOROURACIL-INDUCED CARDIOTOXICITY: ROLE OF CARDIAC BIOMARKERS.
Moghaddam Z; Rostami M; Zeraatchi A; Abadi H; Karamitanha F; Amirmoghaddami H
Exp Oncol; 2022 May; 44(1):60-66. PubMed ID: 35548958
[TBL] [Abstract][Full Text] [Related]
35. Abnormal Dihydropyrimidine Dehydrogenase Activity as an Indicator of Potential 5-Fluorouracil Linked Cardiotoxicity in Colorectal Cancer Patients: Are Toxic Events Inevitable?
Chakwop Ngassa H; Elmenawi KA; Anil V; Gosal H; Kaur H; Mohammed L
Cureus; 2021 Sep; 13(9):e17712. PubMed ID: 34650886
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
Molteni LP; Rampinelli I; Cergnul M; Scaglietti U; Paino AM; Noonan DM; Bucci EO; Gottardi O; Albini A
Breast J; 2010; 16 Suppl 1():S45-8. PubMed ID: 21050310
[TBL] [Abstract][Full Text] [Related]
37. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report.
Kuropkat C; Griem K; Clark J; Rodriguez ER; Hutchinson J; Taylor SG
Am J Clin Oncol; 1999 Oct; 22(5):466-70. PubMed ID: 10521060
[TBL] [Abstract][Full Text] [Related]
38. Cardiotoxicity of 5-flourouracil: two case reports.
Tutkun A; Inanli S; Caymaz O; Ayanoğlu E; Duman D
Auris Nasus Larynx; 2001 Apr; 28(2):193-6. PubMed ID: 11240331
[TBL] [Abstract][Full Text] [Related]
39. Symptomatic cardiotoxicity associated with 5-fluorouracil.
Meyer CC; Calis KA; Burke LB; Walawander CA; Grasela TH
Pharmacotherapy; 1997; 17(4):729-36. PubMed ID: 9250550
[TBL] [Abstract][Full Text] [Related]
40. Is there a role for remote ischemic conditioning in preventing 5-fluorouracil-induced coronary vasospasm?
Chong J; Ho AF; Yap J; Bulluck H; Hausenloy DJ
Cond Med; 2019 Oct; 2(5):204-212. PubMed ID: 32133437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
